Interventional Cardiology Devices Market worth $37.27 billion by 2029
The report "Interventional Cardiology Devices Market by Type (Stents, Structural Heart Devices, Angioplasty Balloons (Drug-Eluting), Angiography Catheters, Plaque Modification Devices (Thrombectomy Devices), Guidewires, Introducer Sheaths) - Global Forecast to 2029", is projected to reach USD 27.80 billion in 2024 and is projected to reach USD 37.27 billion by 2029, at a CAGR of 6.0% during the forecast period.
Browse 379 market data Tables and 62 Figures spread through 367 Pages and in-depth TOC on "Interventional Cardiology Devices Market by Type (Stents, Structural Heart Devices, Angioplasty Balloons (Drug-Eluting), Angiography Catheters, Plaque Modification Devices (Thrombectomy Devices), Guidewires, Introducer Sheaths) - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/minimally-invasive-interventional-cardiology-devices-market-548.html
The interventional cardiology devices market is growth-driven by a few factors, which include the high prevalence of cardiovascular diseases, increased preference for minimally invasive procedures, and advancement in medical technology. Cardiovascular diseases are one of the leading causes of deaths worldwide, and interventions, such as angioplasty, stenting, and other catheter-based procedures, are highly in demand.
“Based on angioplasty stents, the drug-eluting stents segment is expected to grow at the highest CAGR during the forecast period.”
DESs have emerged as a keystone in interventional cardiology since they offer a significant advantage over BMS in the sense of reducing the rate of restenosis and thus improving the outcome of the patient. Anti-proliferative drugs released by the DES inhibit the growth of scar tissue that otherwise leads to re-narrowing of the artery, known as restenosis, following the placement of a stent. The incidence of repeat revascularization procedures is significantly lower with DES than with BMS. The development of DES technology has proceeded into more advanced drug coatings and better stent platforms that have further enhanced safety and efficacy.
“The angiography catheters segment is expected to account for the largest share, by catheters in the interventional cardiology devices market.”
Angiography catheters form the most important interventional tools used in cardiology. They bring lots of benefits in making interventions efficient, safe, and effective. They help facilitate accurate design to allow navigation accuracy within the vascular system in which the catheter could precisely reach specific areas in the heart and into coronary arteries without traumatizing tissues. It further allows good and detailed imaging to enable clinicians at a high resolution to check on arterial blockages, malformations, among other cardiovascular conditions.
“The aortic valve therapy devices segment is expected to account for the largest share, by structural heart devices segment in the interventional cardiology devices market.”
Aortic heart valve devices offer considerable advantages for interventional cardiology as minimally invasive treatment can now be undertaken for aortic stenosis and indeed other valve-related conditions, particularly for high-risk patients considered to be destined for open-heart surgery. Devices used in these new methods are the TAVR systems, where in many instances, it means quicker, less traumatic techniques for these procedures usually entering the patient through a femoral artery catheterization.
“Based on end user, the ambulatory surgical centers account for the second largest share in interventional cardiology devices market.”
Interventional cardiology procedures are being done increasingly at ASCs as the length of time involved in various procedures has been shortening while the pressure on reducing healthcare costs yet effectively delivered still mounts. These centers afford a coordinated outpatient environment and are cheaper compared to in-hospital care; therefore, they attract the patient, as well as the practitioner. Today, due to less invasive techniques and even shorter recovery periods, procedures involving diagnostic angiography, PCIs, and stent placements are performed in these centers.
“North America accounted for the largest share of the interventional cardiology devices market.”
The interventional cardiology devices market in North America is growing highly because of increased prevalence of cardiovascular diseases, an aged population, and minimal development in procedures. Heart disease is the great killer, and so this leads to a higher requirement for innovative and efficient intervention solutions. Key products in this area are stents, catheters, and guidewires, increasing use in the main procedure, which is angioplasty, to improve outcomes as well as reduce recovery time. Besides, favorable government policies, increasing healthcare spending, and the increase of outpatient facilities are driving the market.
Key players in the interventional cardiology devices market
Some of the prominent players operating in the interventional cardiology devices market include Boston Scientific Corporation (US), Medtronic (US), Abbott (US), B. Braun SE (Germany), Terumo Corporation (Japan), Edwards Lifesciences Corporation (US), Koninklijke Philips N.V. (Netherlands), Integer Holdings Corporation (US), Teleflex Incorporated (US), Penumbra, Inc. (US), Cook (US), Cordis (US), iVascular S.L.U (Spain), Biosensors International Group, Ltd (Singapore), BIOTRONIK SE & Co. KG (Germany), AMG International (Germany), ENDOCOR GmbH (Germany), InSitu Technologies, Inc. (US), Meril Life Sciences (India), Alvimedica (Istanbul), Cardionovum GmBH (Germany), Medinol Ltd (Turkey), Wellinq (Netherlands), Balton SP (Poland), Translumina (India).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Interventional Cardiology Devices Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
